Price
$16.71
Decreased by -0.00%
Dollar Volume (20D)
1.07 M
ADR%
8.82
Earnings Report Date (estimate)
Aug 14, 23 (-0.7)
Market Cap.
416.48 M
Shares Float
7.33 M
Shares Outstanding
24.92 M
Beta
0.00
Price / Earnings
-6.96
BPR
51.24
20D Range
15.01 23.18
50D Range
15.01 23.43
200D Range
13.81 30.79
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 15, 23 -0.67
Decreased by -48.89%
-0.60
Decreased by -19.44%
Mar 29, 23 -0.61
Decreased by -74.29%
-0.62
Increased by +2.60%
Nov 14, 22 -0.56
Decreased by -115.38%
-0.50
Decreased by -24.00%
Aug 15, 22 -0.49
Increased by +97.94%
-0.45
Decreased by -19.75%
May 16, 22 -0.45 -0.28
Decreased by -216.84%
Mar 30, 22 -0.35 -0.31
Decreased by -41.62%
Nov 15, 21 -0.26 -0.26
Aug 16, 21 -23.80 -0.16
Decreased by -92.34 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0.00
Decreased by N/A%
-15.40 M
Decreased by -42.59%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-15.02 M
Decreased by -72.73%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-13.02 M
Decreased by -110.61%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-11.77 M
Decreased by -103.76%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-10.80 M
Decreased by -288.39%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-8.70 M
Decreased by -137.23%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-6.18 M
Decreased by -168.05%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-5.78 M
Decreased by -162.26%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.